Healthcare AI Company Market Map
Medical Imaging and Diagnostic AI
Systems that analyze radiology, pathology, and cardiology images and flag findings for clinician review.
Buyer Brief
- Best-fit buyer
- Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
- Primary use case
- Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
- Typical deployment
- Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow
Regulatory clearance is only the starting point. Local performance, workflow fit, alert burden, failure handling, and the exact authorized use determine whether a tool is useful in a specific department.
Companies in This Category
| Company | What it does | Stock or ownership | Research next |
|---|---|---|---|
| Aidoc | Radiology triage AI that flags suspected acute findings such as intracranial hemorrhage and pulmonary embolism to move them up the read list. One of the larger FDA-cleared portfolios in imaging triage. | No direct public shares are available. | Company research Official site |
| Viz.ai | Care coordination built on imaging AI: detects suspected large vessel occlusion stroke and alerts the intervention team directly, compressing time-to-treatment rather than only flagging the scan. | No direct public shares are available. | Company research Official site |
| PathAI | AI for digital pathology, applied to both diagnostic support and pharmaceutical research workflows where consistent slide interpretation is the bottleneck. | No direct public shares are available. | Company research Official site |
| Lunit | Imaging AI concentrated in mammography screening and chest radiography, with a significant deployment base in national screening programs outside the United States. | Direct listing: Korea Exchange KOSDAQ: 328130. | Company research Official site |
| Harrison.ai Radiology | Radiology AI formerly marketed as Annalise.ai, now operating under the Harrison.ai Radiology name across chest X-ray and CT decision support. | No direct public shares are available. | Company research Official site |
| RapidAI | Neurovascular imaging analysis for stroke and aneurysm workflows, widely embedded in comprehensive stroke center protocols. | No direct public shares are available. | Company research Official site |
| GE HealthCare | Public healthcare technology company spanning imaging, ultrasound, monitoring, diagnostics, and AI-enabled software used across hospital workflows. | Direct listing: Nasdaq: GEHC. | Company research Official site |
| Siemens Healthineers | Public medical technology company with imaging, diagnostics, cancer-care, and digital businesses that use AI across equipment and clinical workflow. | Direct listing: Frankfurt and Xetra: SHL. | Company research Official site |
| Philips | Public health technology company using AI across diagnostic imaging, ultrasound, monitoring, informatics, and image-guided therapy. | Direct listings: NYSE: PHG and Euronext Amsterdam: PHIA. | Company research Official site |
| DeepHealth | RadNet subsidiary combining radiology informatics, workflow, and clinical AI across breast, chest, neuro, prostate, thyroid, and other imaging work. | Public parent: RadNet, Nasdaq: RDNT. | Company research Official site |
| Avicenna.AI | CT software that flags urgent and incidental findings, sold as the CINA product family. It covers brain bleeds, large vessel occlusion, pulmonary embolism, aortic dissection and spine fractures, and is used by radiology departments and teleradiology providers. | No current public listing was verified. | Company research Official site |
| ScreenPoint Medical | Transpara reads 2D and 3D mammograms to help a radiologist find breast cancer, rate breast density, and compare a scan against a woman's earlier images. Screening programs are its main buyer. | No current public listing was verified. | Company research Official site |
| Brainomix | Brainomix 360 reads brain scans to support decisions in acute stroke care, and e-Lung measures features on lung CT scans. Hospitals use the stroke product in the treatment window, and drug companies use the lung product as a trial measurement. | No current public listing was verified. | Company research Official site |
| Qure.ai | Qure.ai reads chest X-rays, CT scans and other images to flag findings and move urgent cases up the list. The company says it holds 26 FDA-cleared indications across nine products, and it sells to hospitals, screening programs and public health projects in the United States, India and Africa. | No current public listing was verified. | Company research Official site |
| Therapixel | MammoScreen reads a mammogram and marks the places a radiologist should look again for breast cancer. Therapixel is a French software company, and breast screening programs and radiology groups are its buyers. | No current public listing was verified. | Company research Official site |
| Koios Medical | Koios DS reads ultrasound images of the breast and the thyroid and gives the radiologist a second opinion on whether a lump looks suspicious. The company says the software is FDA cleared, CE marked and a billable procedure. | No current public listing was verified. | Company research Official site |
| JLK | JLK sells MEDIHUB, a family of AI tools that read brain scans and other medical images, with stroke care as the main focus. The company is based in South Korea and its shares trade on the KOSDAQ market. | Direct listing: KOSDAQ: 322510. | Company research Official site |
| AZmed | Rayvolve reads X-rays and marks fractures and chest findings for the radiologist. AZmed is based in Paris and sells to hospital radiology departments in Europe and the United States, and the company says Rayvolve now covers eight FDA-cleared findings. | No current public listing was verified. | Company research Official site |
| BrightHeart | The B-Right platform watches a prenatal ultrasound as it happens and helps the sonographer check that the baby's heart views are complete and read correctly. BrightHeart is based in Paris, and its two products, B-Right Views and B-Right Screen, are both FDA cleared and CE marked. | No current public listing was verified. | Company research Official site |
| Sonio | Sonio follows a fetal ultrasound as it happens, checks that the required views were actually captured, flags findings that look abnormal, and writes the report. The company says it has five FDA clearances in under three years, and Samsung now owns it. | Public parent: Samsung. The exact listed Samsung entity holding the shares was not verified, so no ticker is recorded here. | Company research Official site |
| Odin Vision | CADDIE watches a colonoscopy as it happens and points out polyps the doctor should look at again, and CADU does the same job for a gastroscopy. Odin Vision is a London company, and Olympus bought it in 2023, so the software now sits beside Olympus endoscopy equipment. | Public parent: Olympus Corporation, Tokyo Stock Exchange. | Company research Official site |
| Hologic | Hologic makes breast imaging, surgical and laboratory products for women's health, and its Genius AI Detection software reads 3D mammograms and marks the spots a radiologist should check for cancer. Blackstone and TPG took the company private in April 2026, so its shares no longer trade. | No current public listing. Hologic's shares were delisted from Nasdaq when the take-private closed on 7 April 2026. | Company research Official site |
| Digital Diagnostics | LumineticsCore looks at a photo of the back of the eye and decides on its own whether a person with diabetes has diabetic retinopathy, without an eye doctor reading the image. Primary care clinics are the main buyer, and the company says the result comes back in about 30 seconds. | No current public listing was verified. | Company research Official site |
| Nanox.AI | Reads routine CT scans a patient already had and flags signs of heart, liver, and bone conditions that were not the reason for the scan, so they can be caught earlier. Formerly Zebra Medical Vision. | Public parent: Nano-X Imaging, Nasdaq: NNOX. | Company research Official site |
What to Verify Before Shortlisting
Evidence
- Was the tool tested prospectively and independently on comparable equipment and patients?
- What are sensitivity, specificity, false positive workload, and time-to-action effects?
- How does performance vary by site, scanner, demographic subgroup, and disease prevalence?
Regulatory and workflow
- Which FDA authorization covers the exact product version, modality, and intended use?
- Who retains final clinical responsibility and how is disagreement with the AI handled?
- What post-deployment monitoring and material update notification does the vendor provide?
Data and contracts
- Where are images and derived data processed and retained?
- Which PACS, RIS, pathology, and EHR integrations are supported in production?
- Can data be used for model improvement, and what controls govern secondary use?
The question that matters: Which specific FDA clearance covers which specific finding on which specific modality. A clearance for one use case is not validation for everything the marketing page implies.
Directory inclusion is editorial and does not imply endorsement. Product capabilities, contracts, and regulatory status can change. Verify claims with the company and the relevant regulator before procurement.